What identity data should an Ipamorelin supplier Australia put on a CoA?
When a laboratory shortlists an Ipamorelin supplier Australia, the first documentary test is whether the certificate of analysis identifies the same chemical entity that the catalogue name implies. Ipamorelin is not a linear fragment assembled only from proteinogenic L-amino acids. The accepted research structure is the C-terminally amidated pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2. 2-Aminoisobutyric acid (Aib) occupies the N-terminus; histidine is followed by D-2-naphthylalanine (D-2-Nal) and D-phenylalanine; lysine is present as a carboxamide rather than a free carboxylic acid. That combination of a non-proteinogenic residue, two D-configured amino acids and a C-terminal amide is the identity claim. A supplier who reports only a trivial name and a milligram quantity, without a sequence string, molecular formula or mass, has not yet made an identity statement that an analyst can check.
Orthogonal evidence should sit on the same lot record. Electrospray ionisation mass spectrometry should report the observed mass-to-charge ratio for the protonated molecule, or a clearly assigned multiply charged ion, against the theoretical monoisotopic mass of the free amidated pentapeptide (nominal monoisotopic mass near 711.4 Da). A reversed-phase HPLC chromatogram should give retention time under stated column chemistry, gradient, ion-pair reagent, flow, temperature and detection wavelength, with a sample identifier that matches the vial lot. Tandem mass spectra that support Aib-His connectivity and the aromatic D-2-Nal/D-Phe pair add sequence-level support that a single molecular ion cannot provide.
The peptide belongs historically to the peptidyl growth hormone secretagogue scaffold class. Raun and co-workers described ipamorelin as a selective peptidyl growth hormone secretagogue, which is useful as a chemical-class label when comparing catalogue synonyms (PMID:9849822). Structural studies have mapped peptidyl secretagogue motifs onto ghrelin-related derivatives, so identity is a residue-pattern and termini problem rather than a trade-name problem (PMID:11396951). Work on peptidomimetic secretagogue derivatives used as ghrelin-receptor imaging ligands likewise treats the ligand as a confirmed chemical structure (PMID:30282322). Red flags include omission of Aib, a free C-terminal acid, a molecular weight that matches GHRP-2, GHRP-6 or hexarelin, or a chromatogram with no method header.
How do acetate and TFA counterions change net peptide content on a CoA?
Synthetic amidated pentapeptides are commonly isolated as salts. The counterion contributes to the weighable mass of lyophilised solid and changes how reversed-phase methods are buffered, so an Australian supplier evaluation should rank salt form as a first-class CoA field.
Trifluoroacetate is the default counterion after many preparative purifications that use TFA as an ion-pair reagent. Residual TFA remains bound to basic sites, particularly the lysine side chain and the N-terminus, so the solid may contain a substantial mass fraction of TFA even when HPLC purity is high. Acetate salts are typically produced by counterion exchange. Acetate is still a salt, but its molar mass is lower than TFA, and residual TFA can complicate some downstream chromatographic and spectrometric methods. Neither salt form is intrinsically more pure in the area-percent sense; they are different solids with different mass balances.
Net peptide content is the fraction of the labelled solid that is peptide after correction for counterion, residual water and residual solvents. Two vials with identical HPLC purity and identical labelled milligram mass can contain different amounts of ipamorelin if one is a wet TFA salt and the other is a drier acetate salt. A complete CoA reports identified counterion; counterion content (ion chromatography or fluorine-19 nuclear magnetic resonance for TFA; ion chromatography for acetate); water by Karl Fischer titration; residual solvents where claimed; and net peptide content or an assay value clearly distinguished from area-percent purity.
Buyers comparing suppliers on price per milligram without these fields are not comparing the same material. Request the salt form on the vial label and on the CoA, and do not accept a single purity percentage as net content. Where both acetate and TFA lots exist, the batch report should state which ion-pair system was used for release chromatography. If a CoA is silent on counterion, treat net content as unknown. Local Australian stock and tracked dispatch do not replace these fields; they only mean lot paperwork should arrive with the vial.
How should HPLC area-percent purity be read against assay on supplier paperwork?
Area-percent purity from reversed-phase HPLC is a relative chromatographic result, not a gravimetric assay. The main-peak area is divided by the sum of integrated peak areas, usually after excluding solvent fronts and system peaks. That calculation says nothing about how much peptide is in the vial, nothing about water or counterion, and nothing about impurities that do not absorb at the detection wavelength. For ipamorelin, detection is commonly at 214–220 nm (peptide bond) and near 280 nm where the naphthyl side chain absorbs. A 280 nm-only method will under-report non-aromatic deletion peptides; a 214 nm-only method captures more process-related species but is more sensitive to baseline artefacts.
System suitability belongs on the same record: column identity, particle size, mobile phases, gradient table, flow, temperature, sample load, diluent, detection wavelength, and integration events (slope sensitivity, peak width, reject area). Without those parameters, a 98.5% figure cannot be compared across suppliers. Peak tables should list relative retention time, area percent and, where available, a mass assignment for each related substance above the reporting threshold. Diode-array peak-purity indices are not a substitute for chromatographic resolution; a spectrally pure apex can still hide a co-eluting diastereomer.
Assay and net peptide content answer a different question. Assay may use HPLC against a qualified reference standard, nitrogen determination, or amino-acid analysis after hydrolysis, with Aib and D-2-Nal response factors stated. The CoA should state whether assay is on the as-is solid or on anhydrous, counterion-free peptide. A competent supplier presents HPLC related-substances purity and a separate content result. When two lots both claim greater than 98%, inspect chromatogram scale, ignore limit, isomer resolution, and whether net content sits within a stated range. If only one number is offered, Australian unit-price comparisons are not chemically valid.
Which related substances and analogue mix-ups should lot data flag?
Related substances for ipamorelin are not a generic impurity list. Because the sequence is only five residues, a single deletion, epimerisation or terminus error is a large fractional change in structure. Typical process-related species include truncated sequences (des-Aib, des-Lys amide), failure sequences from incomplete couplings, incompletely amidated C-terminal acid, and diastereomers at D-2-Nal or D-Phe. Several of those species can co-elute with the main peak on a shallow C18 gradient, which is why a single-peak CoA without a related-substances table is weak evidence.
Mass spectrometry is the practical filter. The free amidated pentapeptide clusters near 711.4 Da. The C-terminal free acid differs in mass and is often chromatographically distinct under ion-pair conditions. Deletion of Aib or lysine produces larger mass shifts that should not be dismissed as adducts. Sodium, potassium and TFA adducts and doubly charged ions should be assigned explicitly so they are not tabulated as unrelated peptides.
A second class of error is catalogue mix-up with other peptidyl growth hormone secretagogue ligands. GHRP-6, GHRP-2 and hexarelin are different sequences with different monoisotopic masses and different aromatic substitution patterns. A CoA that quotes a molecular weight appropriate to hexarelin or GHRP-2 is not an ipamorelin identity record. Structural literature comparing peptidyl secretagogues with ghrelin-derived motifs underlines that small scaffold changes must be distinguished analytically (PMID:11396951). Growth hormone-releasing peptide literature likewise assumes a defined ligand structure rather than a catalogue synonym (PMID:11322495). Peptidomimetic secretagogue derivatives prepared as ghrelin-receptor imaging ligands show how closely related chemotypes remain distinct entities (PMID:30282322).
Acceptance criteria should be numerical: a minimum HPLC purity, a maximum individual unspecified impurity, a mass-accuracy window for the molecular ion, and no named analogue above the reporting threshold. Australian supply should change how quickly lot-matched chromatograms and mass spectra can be obtained, not the chemical tests themselves.
What lot-traceability fields belong on an Australian research procurement checklist?
Traceability is the ability to connect a physical vial to a specific analytical dataset without ambiguity. The chain should include a unique lot number on the vial, the same number on the CoA, the same number in the chromatogram header and mass-spectrum file, and a product code that matches the sequence claimed. Quantity on the CoA should match the labelled vial fill, described as lyophilised solid with stated appearance. Multi-vial orders should state whether vials share one lot.
Australian fulfilment details that help a laboratory are local stock status, order cut-off, tracked dispatch, and a lot-matched CoA PDF supplied with the parcel. A tracked consignment note is logistics evidence, not identity evidence. Concordance checks at goods-in should compare peptide name, salt form, lot and fill mass between PDF and vial. Missing method conditions or a chromatogram that appears reused across unrelated peptides are grounds to quarantine the material.
Before purchase, request a current-lot CoA and confirm these fields are populated: sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2; molecular formula; theoretical and observed mass; HPLC retention time with method identifier; area-percent purity at a stated wavelength; related-substances table; counterion identity and content; water; net peptide content or assay with the as-is versus anhydrous basis; lot number; dates; appearance; and quality sign-off. Convert price to a content-adjusted figure only when net peptide content is reported. Prefer lots that include both HPLC and mass spectrometry on the same document.
After goods-in, repeat a minimum identity check if the laboratory has HPLC or MS, and record the supplier lot in inventory. Ipamorelin’s original description as a selective peptidyl growth hormone secretagogue (PMID:9849822) is relevant only as the reason the sequence is a named entity with look-alike analogues that must be excluded by mass and chromatography. If a supplier declines lot-matched HPLC-MS, counterion and net-content fields, the laboratory is buying a label rather than a characterised pentapeptide.
Order Ipamorelin with documentation
If this guide helped you evaluate Ipamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Ipamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What documents should I request from an Ipamorelin supplier Australia before ordering?
Request a lot-matched certificate of analysis that states the pentapeptide sequence, theoretical and observed mass, HPLC method and area-percent purity, a related-substances peak table, counterion identity, water content, and net peptide content or assay. The lot number on the PDF must match the vial. Chromatogram and mass spectrum figures with method headers should be included. Research use only.
Why does acetate versus TFA matter if HPLC purity looks high?
HPLC area-percent purity describes the related-substances profile of the peptide peak, not the mass fraction of peptide in the lyophilised solid. TFA and acetate contribute different amounts of non-peptide mass, and residual water varies by lot. Without counterion and net peptide content, two high-purity lots are not comparable on a per-milligram basis. Ask the supplier to state salt form on both the CoA and the vial label.
Is HPLC purity the same as net peptide content?
No. Area-percent purity is a relative chromatographic ratio. Net peptide content corrects the solid for counterion, water and residual solvents, and assay is a separate content measurement against a stated basis. A receiving specification should list both a purity limit and a content result. If only one percentage appears on the CoA, content remains unknown.
How do I confirm the CoA belongs to the vial I received?
Match peptide name, salt form, lot or batch number, and fill mass between the vial label and the CoA header. The chromatogram header and mass-spectrum identifier should carry the same lot. If those fields disagree, quarantine the vial and request a corrected lot record before any laboratory use of the solid.
Which analogue mix-ups should mass data exclude?
Compare the observed molecular ion with the theoretical mass of amidated ipamorelin near 711.4 Da. GHRP-2, GHRP-6 and hexarelin are different sequences with different masses and should not appear as the assigned identity. Also flag a C-terminal free acid and deletion sequences. Mass assignments belong on the same lot record as the HPLC peak table.
References
- PMID:9849822 — Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol — 1998
- PMID:11396951 — Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues — Biochem Biophys Res Commun — 2001
- PMID:11322495 — Do growth hormone-releasing peptides act as ghrelin secretagogues? — Endocrine — 2001
- PMID:30282322 — Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor — Eur J Med Chem — 2018
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
